Source comparison
Thymosin Alpha-1 Autoimmune Support Results Timeline Expect: Comparison
Weeks 1–3 Minimal. Baseline cytokine fluctuations only None to negligible Injection routine established, no felt effects, frustration common Too early for meaningful assessment. Continue protocol Weeks 4–6 CD4/CD8 ratio begins normalizing, IL-6 and TNF-alpha d
This comparison does not assign a generated winner or score.
- Weeks 1–3
- Minimal. Baseline cytokine fluctuations only
- None to negligible
- Injection routine established, no felt effects, frustration common
- Too early for meaningful assessment. Continue protocol
- Weeks 4–6
- CD4/CD8 ratio begins normalizing, IL-6 and TNF-alpha decline 15–20%
- Subtle energy improvement in 30–40% of patients, pain unchanged
- Some notice reduced brain fog or slightly better sleep, most feel nothing
- First valid checkpoint. Recheck inflammatory markers
- Weeks 8–12
- Treg expansion 25–35%, anti-inflammatory IL-10 elevated, autoantibody titers declining
- Joint pain reduced 20–30%, skin clarity improving, fatigue lessening
- Noticeable symptom relief begins. This is the inflection point most patients recognize
- Reassess dosing if no symptom improvement by week 12
- Weeks 16–20
- Treg plateau reached, sustained cytokine balance, tissue inflammation resolving
- Symptom improvement stabilizes at 40–50% reduction from baseline
- Patients describe feeling 'normal' for first time in months or years
- Transition to maintenance dosing or taper consideration
- Beyond 20 weeks
- Maintenance of immune balance, no further Treg expansion
- Continued symptom control if dosing maintained, gradual return if stopped
- Dependency question emerges. Is this a long-term protocol or finite intervention?
- Individualize based on autoimmune condition severity and relapse history